GSK Plc ADR (NYSE:GSK) has a beta value of 0.66 and has seen 0.86 million shares traded in the recent trading session. The company, currently valued at $79.98B, closed the recent trade at $39.22 per share which meant it gained $0.26 on the day or 0.65% during that session. The GSK stock price is -17.08% off its 52-week high price of $45.92 and 14.15% above the 52-week low of $33.67. If we look at the company’s 10-day average daily trading volume, we find that it stood at 6.99 million shares traded. The 3-month trading volume is 4.04 million shares.
The consensus among analysts is that GSK Plc ADR (GSK) is Buy stock at the moment, with a recommendation rating of 2.32. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 4 out of 8 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 1.24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
GSK Plc ADR (NYSE:GSK) trade information
Sporting 0.65% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the GSK stock price touched $39.22 or saw a rise of 2.85%. Year-to-date, GSK Plc ADR shares have moved 5.81%, while the 5-day performance has seen it change -2.55%. Over the past 30 days, the shares of GSK Plc ADR (NYSE:GSK) have changed -7.86%. Short interest in the company has seen 10.36 million shares shorted with days to cover at 3.03.
Wall Street analysts have a consensus price target for the stock at $53, which means that the shares’ value could jump 26.0% from the levels at last check today. The projected low price target is $36.0 while the price target rests at a high of $85.0. In that case, then, we find that the latest price level in today’s session is -116.73% off the targeted high while a plunge would see the stock lose 8.21% from the levels at last check today.
GSK Plc ADR (GSK) estimates and forecasts
Figures show that GSK Plc ADR shares have underperformed across the wider relevant industry. The company’s shares have lost -0.97% over the past 6 months, with this year growth rate of 7.25%, compared to 17.40% for the industry. Revenue growth from the last financial year stood is estimated to be 10.40%.
3 analysts offering their estimates for the company have set an average revenue estimate of 10.82B for the current quarter. 3 have an estimated revenue figure of 10.54B for the next ending quarter. Year-ago sales stood 9.44B and 9.99B respectively for this quarter and the next, and analysts expect sales will grow by 14.60% for the current quarter and 10.40% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 4.23% over the past 5 years. Earnings growth for 2024 is a modest 3.84% while over the next 5 years, the company’s earnings are expected to increase by 6.46%.
GSK Dividends
GSK Plc ADR is expected to release its next earnings report on 2024-Oct-30 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue. The forward dividend is 1.54 at a share yield of 3.92%. The company’s dividend yield has gone up over the past 12 months, with a 5 Year Average Dividend Yield of 4.83%.
GSK Plc ADR (NYSE:GSK)’s Major holders
Insiders own 0.06% of the company shares, while shares held by institutions stand at 15.48% with a share float percentage of 15.49%. Investors are also buoyed by the number of investors in a company, with GSK Plc ADR having a total of 1013.0 institutions that hold shares in the company. The top two institutional holders are DODGE & COX with over 68.34 million shares worth more than $2.63 billion. As of 2024-06-30, DODGE & COX held 1.6795% of shares outstanding.
The other major institutional holder is FMR LLC, with the holding of over 26.78 million shares as of 2024-06-30. The firm’s total holdings are worth over $1.03 billion and represent 0.6583% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Dodge & Cox Stock Fund and Vanguard/Primecap Fund. As of Jun 30, 2024, the former fund manager holds about 2.41% shares in the company for having 50.05 shares of worth $1.96 billion while later fund manager owns 10.13 shares of worth $396.76 million as of Jun 30, 2024, which makes it owner of about 0.49% of company’s outstanding stock.
